Medication info
Exmet 50/850 mg

Exmet 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Dark pink oval film-coated tablet
Packaging
56 tablets/box [14 tablets/PTP×4], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202204571 · Approved 2022.12.21 · Insurance code 671707260

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose of 100 mg) and the patient’s existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose of 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in combination with sitagliptin and metformin, designed to assist in blood sugar control for patients with Type 2 diabetes. It effectively lowers blood sugar levels alongside diet and exercise therapy, thus serving as a good treatment option for patients struggling with blood sugar management.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or for patients whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose of 100 mg) and the patient’s existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose of 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains two components, sitagliptin and metformin, primarily used for blood sugar control in Type 2 diabetes patients. During the usage of this medication, severe allergic reactions may occur; if symptoms such as skin rash, hives, or difficulty breathing develop, discontinue use immediately and consult a doctor. There is a risk of acute pancreatitis, so if symptoms such as abdominal pain, nausea, or vomiting occur, notify healthcare personnel right away. Severe side effects like hypoglycemia or lactic acidosis may arise, thus this medication should not be used, especially by patients with impaired kidney function or liver dysfunction. In cases of poor kidney function or acute illness, or around the time of surgery, the use of this medication should be temporarily halted and may be reinitiated only after kidney function recovers to normal. This medication is not recommended for use during pregnancy or breastfeeding, and its safety and efficacy in pediatric patients under 18 years of age have not been established. Regular blood sugar and kidney function tests are necessary during treatment, and since vitamin B12 deficiency may occur, regular blood tests are advised. Excessive alcohol consumption can increase the risk of lactic acidosis; hence, avoiding alcohol is advisable. When used in conjunction with other hypoglycemic agents, particularly insulin or sulfonylurea medications, the risk of hypoglycemia may increase, necessitating dose adjustment. If severe joint pain or skin blistering occurs during medication, consult a physician immediately, and medication may need to be discontinued. It is important to consistently maintain diet and exercise therapy while taking this medication and to regularly consult healthcare professionals to monitor treatment effects and side effects.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • vesiculobullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • reduced appetite
  • itching
  • dermatitis
  • anorexia
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air exposure, and it is advisable to keep it at room temperature between 1°C and 30°C. This helps to maintain the drug's efficacy and prevent degradation.

Appearance and packaging

Appearance

Dark pink oval film-coated tablet

Package unit

56 tablets/box [14 tablets/PTP×4], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.